New molecular entity
Development and Regulatory status
Nov 19Development in pancreatic cancer discontinued .
A pegylated formulation of recombinant human hyaluronidase. Numerous solid tumours, including pancreatic, develop a hyaluronan coating that is thought to be associated with an increased resistance to to anti-cancer therapeutic agents.
Peak incidence for pancreatic cancer is in the seventh and eighth decades of life. There is no difference in incidence between the sexes. Due to poor survival rates, incidence and mortality rates are similar at approximately 9 per 100,000 population per annum .